Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Address: Csorsz ut 49-51 H-1124 Budapest,Hungary
Tel: +36 1 577 8200
Web: http://www.astellas.com/worldwide.html
Astellas Pharma Europe the world’s 20 largest pharmaceutical company, belonging to 15 thousand employees worldwide Astellas Pharma Inc. subsidiary. As a young and forward-looking company Astellas aims to improve the quality of life for people around the world, innovative and reliable pharmaceutical products, by providing products.
In 2005, Yamanouchi and Fujisawa merger created Astellas remains committed to the class of the first (‘first-in-class’), and class best (‘best-in-class’) products developed for the key therapeutic areas by combining high R & D and marketing opportunities in the pharmaceutical world market continued growth.
In October 2006, Astellas has launched a company called Vision 2015 management strategy. Declared goal is to világelsőkké within that category (GAL) to become a number of therapeutic areas where further innovation of the patients currently unmet needs can be met. The company’s vision is an integral part in 2008, launched a wide-ranging Changing TOMORROW ™ (‘Change your tomorrow’) campaign, which displays the company’s ability to create a brighter future stakeholders, especially patients.
Significant, ongoing investments in research and development will further strengthen research-based Astellas pharmaceutical company capacity by providing effective medicines for patients worldwide, and continues to doctors and trusted partner of network deployment.
In Europe the main strengths of the Astella organ transplantation, urology, dermatology and anti-infective agents and the therapeutic areas of pain prevail. In addition, Astellas aims to develop a gyógyszerportfóliót the needs of cancer patients.
Astellas Pharma Europe Ltd. is based in Staines near London, and operates sales subsidiaries throughout Europe and the CIS states and South Africa. Astellas Pharma International, as well as licensors and distributors, the company responsible for the Middle East and Africa sales as well.
Geninax® : an oral new-type quinolone antibacterial agent
Celecox® : the selective COX-2 lnhibitor
Lipitor® : a treatment for hypercholesterolemia
Micardis® : a treatment for hypertension
Gaster® : a treatment for peptic ulcers and gastritis
Luvox® : an antidepressant
Myslee® : a hypnotic
Cefzon® : an oral cephalosporin
Seroquel® : an antipsychotic agent
Dorner® : a treatment for chronic arterial occlusion
Nasea® : a 5-HT3 (receptor) antagonist
Targocid® : a glycopeptide antibiotic
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in…
Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance…
Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and…
Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient…
Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG…
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology…
See our Cookie Privacy Policy Here
